The following information is intended as a resource for journalists only and was factually correct at the time it was issued.
Follow AbbVie UK
RINVOQ® ▼(upadacitinib) Granted EU Marketing Authorisation for the Treatment of Eligible Adults with Moderate to Severe Active Rheumatoid Arthritis
Dec 18, 2019
Results from Upadacitinib Phase 3 SELECT-COMPARE Study Published in Arthritis and Rheumatology
Results from Upadacitinib Phase 3 SELECT-MONOTHERAPY Study Published in The Lancet